The data for the numerator come from the “TB treatment” column of the pre–antiretroviral therapy and antiretroviral therapy registers. Among those newly enrolled in HIV care during the reporting period, those receiving TB treatment at time of enrollment and those starting TB treatment during the reporting period should both be included in the numerator. The data needed for this indicator are more difficult to collect if TB diagnosis and treatment are not carried out on the same site as HIV testing or treatment and care. This situation will require establishing reliable two-way communication between the TB service and the HIV treatment and care services. The denominator data are obtained by adding those retained on treatment at the beginning of the reporting period to those newly enrolled in the program during the reporting period. The data for this indicator should be reported disaggregated by antiretroviral therapy and pre– antiretroviral therapy registers. The numerator data from the antiretroviral therapy register are used as the basis of the indicator on the co-management of TB and HIV treatment: the number of adults and children on the antiretroviral therapy registers starting TB treatment during the last year as a proportion of the estimated HIV-positive TB cases at the country level. WHO provides this estimate for this UNGASS indicator on an annual basis in the global TB control report. Tool: pre–antiretroviral therapy and antiretroviral therapy registers; the data are collated on the cross- sectional quarterly reporting formats Frequency: data would be collected continuously and reported quarterly to the national level and annually to WHO